EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DURABLE 8-YEAR CLINICAL AND STRUCTURAL OUTCOMES FOLLOWING ULTRASOUND-GUIDED AUTOLOGOUS BONE MARROW ASPIRATE CONCENTRATE INJECTION FOR PARTIAL-THICKNESS SUPRASPINATUS TEARS

Don Buford, MD, William Murrell, MD

Biologic Orthopedics Journal · 22.07.2026 · 8 (1) · 1-19

DOI: 10.22374/boj.v8i1.87 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biologic Orthopedics Journal, online erschienen am 22.07.2026. Verfasst von Don Buford und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Partial-thickness rotator cuff tears (pRCTs) are among the most common causes of shoulder pain and disability in adults. Conventional nonoperative care—physical therapy, NSAIDs, and corticosteroid injection—relieves symptoms but does not restore tendon integrity. Bone marrow aspirate concentrate (BMAC) may provide a biologically active stimulus for structural tendon repair, yet long-term outcome data for BMAC injection without concurrent surgery are lacking.

Objective

To evaluate the durability of clinical and structural outcomes at a minimum of 7 years following ultrasound-guided autologous BMAC injection for partial-thickness supraspinatus tendon tears, and to report the rate of surgical avoidance.

Methods

Retrospective analysis of a prospectively maintained single-practice registry (STROBE-compliant). Twenty-four consecutive patients with ultrasound-confirmed partial-thickness supraspinatus tears received a standardized, ultrasound-guided, multitarget autologous BMAC injection (~12 mL, prepared from 120 mL of iliac crest aspirate by two-spin centrifugation). The primary outcome was change in the Single Assessment Numeric Evaluation (SANE) score from baseline to final follow-up; secondary outcomes were the Numeric Pain Score (NPS), ultrasound-assessed tear size (% of tendon thickness), and surgical avoidance rate. The study endpoint was August 1, 2025.

Results

Five of 24 patients (20.8%) progressed to surgery and were analyzed separately. Among the 19 non-surgical patients (mean age 48.9 years; mean follow-up 8.4 ± 0.7 years [range 7.0–9.1]), SANE improved from 48 to 82 (mean +34 points; p < 0.001) and NPS from 4.6 to 2.1 (mean −2.5 points; p < 0.001). Mean tear size decreased from 48.9% to 27.9% of tendon thickness (−21.0 percentage points). Complete structural healing (0% tear) occurred in 31.6% (6/19), and 73.7% demonstrated complete healing or improvement. The overall surgical avoidance rate was 79.2%.

Conclusions

Ultrasound-guided autologous BMAC injection for partial-thickness supraspinatus tears was associated with durable improvements in pain and function, a meaningful rate of complete structural healing, and a high rate of surgical avoidance at long-term follow-up exceeding 8 years. These hypothesis-generating findings warrant investigation in prospective, controlled trials.Level of Evidence: IV (retrospective case series).

Zitieren

APA

Buford, D., MD, Murrell, W., & MD (2026). DURABLE 8-YEAR CLINICAL AND STRUCTURAL OUTCOMES FOLLOWING ULTRASOUND-GUIDED AUTOLOGOUS BONE MARROW ASPIRATE CONCENTRATE INJECTION FOR PARTIAL-THICKNESS SUPRASPINATUS TEARS. Biologic Orthopedics Journal, 8(1), 1-19. https://doi.org/10.22374/boj.v8i1.87

Vancouver

Buford D, MD, Murrell W, MD. DURABLE 8-YEAR CLINICAL AND STRUCTURAL OUTCOMES FOLLOWING ULTRASOUND-GUIDED AUTOLOGOUS BONE MARROW ASPIRATE CONCENTRATE INJECTION FOR PARTIAL-THICKNESS SUPRASPINATUS TEARS. Biologic Orthopedics Journal. 2026;8(1):1-19. doi:10.22374/boj.v8i1.87

BibTeX
@article{Buford2026,
  author = {Buford, Don and MD and Murrell, William and MD},
  title = {DURABLE 8-YEAR CLINICAL AND STRUCTURAL OUTCOMES FOLLOWING ULTRASOUND-GUIDED AUTOLOGOUS BONE MARROW ASPIRATE CONCENTRATE INJECTION FOR PARTIAL-THICKNESS SUPRASPINATUS TEARS},
  journal = {Biologic Orthopedics Journal},
  year = {2026},
  volume = {8},
  number = {1},
  pages = {1--19},
  doi = {10.22374/boj.v8i1.87}
}
Kostenlos starten →